医学
生活质量(医疗保健)
达沙替尼
髓系白血病
内科学
尼罗替尼
伊马替尼
不利影响
共病
酪氨酸激酶抑制剂
人口
癌症
物理疗法
肿瘤科
环境卫生
护理部
作者
Hayri Bostan,Tayfur Toptaş,Funda Pepedil Tanrıkulu,Kevser Kut,Fatma Arıkan,Fergün Yılmaz,Işık Kaygusuz Atagündüz,Tülin Firatli‐Tuglular
标识
DOI:10.1016/j.clml.2020.08.009
摘要
Abstract
Background
With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age- and gender-matched healthy populations. Nevertheless, patients receiving TKIs report chronic adverse events such as fatigue, edema, and muscle cramps, which lead to a decrease in their quality of life (QoL). Therefore, the aim of this study was to assess the QoL and symptom burden in patients receiving original imatinib, generic imatinib, dasatinib, and nilotinib. Patients and Methods
A total of 121 patients with CML who received TKIs for at least 3 months were enrolled in the study. The QoL was assessed with the Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and Quality of Life Questionnaire-Chronic Myeloid Leukemia (QLQ-CML24) modules. The symptom burden was assessed with MD Anderson Symptom Inventory for Chronic Myeloid Leukemia (MDASI-CML) and EORTC QLQ-CML24. Results
The median age of the study population was 53 years (range, 28-90 years), and 83 (81.4%) patients had a low-to-medium Sokal risk score. The Eastern Cooperative Oncology Group performance status of most patients were good (< 2; 96%), and comorbidity scores were low (HCT-CI < 3; 90.8%). There was no significant difference between the general health status of patients in terms of EORTC QLQ-C30 and QLQ-CML24. According to the results of the MDASI-CML and QLQ-CML24 modules, the most common symptom was fatigue (58.7%) in all groups, and there were no significant differences between the groups in terms of the effects on the daily life activities of the patients. Conclusion
Patients with CML receiving first- and second-generation TKIs were seen to have a similar QoL and symptom burden.
科研通智能强力驱动
Strongly Powered by AbleSci AI